Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guoxiang Shen

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Chemical Research in Toxicology|February 3, 2012
Cytochrome P450 11A1 bioactivation of a kinase inhibitor in rats: use of radioprofiling, modulation of metabolism, and adrenocortical cell lines to evaluate adrenal toxicityDonglu Zhang, Oliver Flint, Lifei Wang, et al.
Bioorganic & Medicinal Chemistry Letters|May 26, 2017
Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitorsJohn Hynes, Hong Wu, James Kempson, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid ArthritisSteven H Spergel, Michael E Mertzman, James Kempson, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2014
Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitorsJames J-W Duan, Zhonghui Lu, Bin Jiang, et al.
Journal of Medicinal Chemistry|March 6, 2009
Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamilyGretchen M Schroeder, Yongmi An, Zhen-Wei Cai, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Chemical Research in Toxicology|February 3, 2012
Cytochrome P450 11A1 bioactivation of a kinase inhibitor in rats: use of radioprofiling, modulation of metabolism, and adrenocortical cell lines to evaluate adrenal toxicityDonglu Zhang, Oliver Flint, Lifei Wang, et al.
Bioorganic & Medicinal Chemistry Letters|May 26, 2017
Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitorsJohn Hynes, Hong Wu, James Kempson, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid ArthritisSteven H Spergel, Michael E Mertzman, James Kempson, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2014
Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitorsJames J-W Duan, Zhonghui Lu, Bin Jiang, et al.
Journal of Medicinal Chemistry|March 6, 2009
Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamilyGretchen M Schroeder, Yongmi An, Zhen-Wei Cai, et al.
Pageof 5